Treatment of diabetes mellitus and insulin receptor signal transduction
US5861266A · kind A · utility
8Cited by
1References
26Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 28, 1994 |
| Grant date | Jan 19, 1999 |
| Priority date | — |
| Expiry date | Feb 28, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel modalities of treatment of diabetes, and other diseases caused by dysfunctional signal transduction by insulin receptor type tyrosine kinases (IR-PTK). Applicants discovered that IR-PTK activity may be modified by modulating the activity of a tyrosine phosphatase, and IR-PTK signal transduction may be triggered even in the absence of ligand. Methods for identifying compounds that, by modulating RPTP.alpha. or RPTP.epsilon. activity, elicit or modulate insulin receptor signal transduction are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.